Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs)

Cancer and Metastasis Reviews

Volumn 12, Issue 2, 1993, Pages 135-151

  Denny, William A ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

bioreductive drugs; cobalt (III) complexes; drug diffusion; nitrogen mustards; SN 23862; SN 24771

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANILINE MUSTARD; AZIRIDINE DERIVATIVE; CHLORAMBUCIL; CHLORMETHINE; COBALT COMPLEX; HYDRALAZINE; MELPHALAN; MISONIDAZOLE; MITOFLAXONE; PORFIROMYCIN; SN 23816; SN 23862; SN 24699; SN 24771; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CYTOTOXICITY; DNA CROSS LINKING; DRUG ACTIVATION; DRUG DESIGN; DRUG METABOLISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; HUMAN; HYPOXIA; NONHUMAN; OXIDATION REDUCTION REACTION; OXYGEN TISSUE LEVEL; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR BLOOD FLOW;

ANIMAL; CELL CYCLE; CELL HYPOXIA; COMPARATIVE STUDY; CYTOTOXINS; DIFFUSION; DRUG DESIGN; HUMAN; MOLECULAR STRUCTURE; NEOPLASMS; NITROGEN MUSTARD COMPOUNDS; OXIDATION-REDUCTION; PRODRUGS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027219332     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/BF00689806     Document Type: Article

References (90)

1. Zur Keuntnis des Bedingungen der Biologischen Wirkung der Rontgenstrahlen
2. Experimental radiotherapy
3. Henk JM, Smith CW: Radiotherapy and hyperbaric oxygen in head and neck cancer. Lancet: 104–105, 1977
4. Misonidazole combined with split course radiotherapy in treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study
5. Definitive evidence for hypoxic cells influencing cure in cancer therapy
6. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy
7. Tumour hypoxia: challenges for cancer chemotherapy
8. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro
9. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9
10. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice
11. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233
12. Intermittent blood flow in a murine tumor: radiobiological effects
13. Therapeutic advantage of hypoxic cells in tumors: a theoretical study
14. Targeting bioreductive drugs to tumours: is it necessary to manipulate blood flow?
15. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors
16. Reoxygenation and repopulation in irradiated tumors
17. Role of glutathione in the hypoxic cell cytotoxicity of misonidazole
18. Induction of hypoxia in normal and malignant tissue by changing the oxygen affinity of haemoglobin - implications for therapy
19. Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT)
20. Exploitation of bioreductive agents with vasoactive drugs
21. Hypoxia-targetted chemotherapy: a role for vasoactive drugs
22. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069. Evidence for therapeutic gain
23. Induction of tumour hyoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo
24. Drug induced perturbations in tumor blood flow: therapeutic potential and possible limitations
25. Manipulation of tumour oxygenation by hydralazine increases the potency of bioreductive radiosensitizers and enhances the effect of melphalan in experimental tumours
26. The effects of single dose oral hydralazine on blood flow through human lung tumors
27. Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine:: Effects on responses to radiation and to the bioreductive toxicity of misonidazole and RSU 1069
28. Manipulations of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU 1069
29. Hydralazine does not increase hypoxia in tumors growing in preirradiated tissue
30. Blood flow failure as a major determinant in the antitumour action of flavone acetic acid (NSC 347512)
31. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma
32. Role of tumor necrosis factor in flavone acetic acidinduced tumor vasculature shutdown
33. Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid
34. Pharmacological modification of tumor blood flow: lack of correlation between alteration of mean arterial blood pressure and changes in tumor perfusion
35. Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid
36. Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs
37. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma
38. Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1α1,2
39. Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (RO-07-0582) in HeLa and Chinese hamster ovary cells
40. Sensitizing and toxicity properties of misonidazole and its derivatives
41. Activation of radiosensitizers by hypoxic cells
42. Evaluation of nitroheterocyclic radiosensitizers using spheroids
43. Cytotoxic effects of the hypoxic cell radiosensitizer Ro 7-0582 to tumor cells in vivo
44. Use of a high frequency ultrasound microscope to image the action of 2-nitroimidazoles in multicellular spheroids
45. Binding of misonidazole to V79 spheroids and fragments of Dunning rat prostatic and human colon carcinomas in vitro: diffusion of oxygen and reactive metabolites
46. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells
47. Mechanisms of activation of Mitomycin C and AZQ in aerobic and hypoxic mammalian cells
48. Dosimetric aspects of radiolabelled antibodies for tumour therapy
49. Antibody-directed enzyme/prodrug therapy (ADEPT)
50. Decreased NADPH: cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions
51. Acid pH in tumors and its potential for therapeutic exploitation
52. Potentiation of the tumor cytotoxicity of melphalan by vasodilating agents
53. Hypoxiaselective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumour cells for substituted N,N-bis(2-chloroethyl) anilines
54. Influence of pH on the cytotoxic activity of chlorambucil
55. The effect of hypoxia and low pH on the cytotoxicity of chlorambucil
56. Cell kinetics and chemotherapy: A critical review
57. Molecular orbital calculations on tumor-inhibitory phenyl aziridines: QSARs
58. Molecular structure and antitumour activity of alkylating agents
59. A marker for hypoxic cells in tumours with potential clinical applicability
60. A novel technique for measuring human tissue pO2 at the cellular level
61. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours
62. Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection
63. Proliferative and oxygenation status in spontaneous canine tumors: an immunocytochemical approach
64. Distribution of misonidazole adducts in 9L gliosarcoma tumors and spheroids: implications for oxygen distribution
65. The radiation sensitivities of R3327-H and R3327-AT rat prostate adenocarcinomas
66. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole
67. Non-invasive assessment of human tumour hypoxia with123I-iodoazomycin arabinoside: preliminary report of a clinical study
68. Oxygen diffusion and oxygen depletion problems in radiobiology
69. DNA-binding nitroheterocycles as hypoxia-selective cytotoxins
70. Structure-activity relationships in antitumor aniline mustards
71. Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells
72. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells
73. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)
74. Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species
75. The properties of total adducts and interstrand crosslinks in the DNA of cells treated with CB 1954: exceptional frequency and stability of the crosslink
76. Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide)
77. Structure, reactivity, spectra and redox properties of cobalt (III) hexamines
78. Kinetics of ammonia detachment from reduced cobalt (III) complexes based on conductometric pulse radiolysis
79. Oxidation of cobalt (II) amine complexes to mononuclear cobalt (III) complexes by dioxygen
80. Binuclear dioxygen complexes of cobalt
81. Coordination complexes of ethyleneimine with Co(III), Cr(III), Pd(II), Pt(II) and Pt(IV)
82. Synthesis and characterization of aziridine complexes of cobalt (III) and chromium (III) designed as hypoxia-selective cytotoxins. X-ray crystal structure of trans[Co(Az)2(NO2)2]Br2.2H2O
83. Cytotoxicity, radiosensitization, antitumor activity and interaction with hyperthermia of a Co(III) mustard complex
84. Kinetics and mechanism of ligand dissociation of cobalt (II)-polyamine complexes in aqueous solution
85. Radiation survival of cells from spheroids grown in different oxygen concentrations
86. Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide